what are the differences between glp 1 medications Pills vs. Pens: Ultimate Comparison of Oral and Injectable GLP-1s Compare GLP-1 Options | Ozempic

Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease

People in the obesity group regained about 0.5%, while those in the diabetes group lost an additional 1.3% on average, though individual outcomes varied

90% of the 38 million type 2 diabetics in the US are overweight

In the interim, continued shared decision making with patients and clinical vigilance for pancreatic diseases in patients on GLP-1RA therapy remains prudent

Or if taking the drugs indefinitely is safe

A team of researchers from the University of Iowa has unveiled concerns about the use of semaglutide, a widely prescribed GLP-1 receptor agonist for type 2 diabetes and obesity, in patients with neuroendocrine neoplasms (NENs)